CN106563124A - Application of lipoic acid as vaccine adjuvant - Google Patents
Application of lipoic acid as vaccine adjuvant Download PDFInfo
- Publication number
- CN106563124A CN106563124A CN201610913659.5A CN201610913659A CN106563124A CN 106563124 A CN106563124 A CN 106563124A CN 201610913659 A CN201610913659 A CN 201610913659A CN 106563124 A CN106563124 A CN 106563124A
- Authority
- CN
- China
- Prior art keywords
- vaccine
- lipoic acid
- application
- adjuvant
- rabbits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 title claims abstract description 15
- 235000019136 lipoic acid Nutrition 0.000 title claims abstract description 13
- 229960002663 thioctic acid Drugs 0.000 title claims abstract description 13
- 239000012646 vaccine adjuvant Substances 0.000 title claims description 4
- 229940124931 vaccine adjuvant Drugs 0.000 title claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 22
- 229960005486 vaccine Drugs 0.000 abstract description 19
- 239000002671 adjuvant Substances 0.000 abstract description 13
- 206010034107 Pasteurella infections Diseases 0.000 abstract description 5
- 201000005115 pasteurellosis Diseases 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 241000606860 Pasteurella Species 0.000 description 6
- 238000002649 immunization Methods 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010010075 Coma hepatic Diseases 0.000 description 2
- 241000606856 Pasteurella multocida Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 201000001059 hepatic coma Diseases 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 229940051027 pasteurella multocida Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
硫辛酸作为兔巴氏杆菌病疫苗佐剂的应用，能够显著提高免疫效率降低死亡率，并且安全、有效、不会引起毒副作用。The application of lipoic acid as an adjuvant for rabbit pasteurellosis vaccine can significantly improve immune efficiency and reduce mortality, and is safe and effective without causing toxic and side effects.
Description
技术领域technical field
本发明涉及硫辛酸作为疫苗佐剂的应用。The present invention relates to the application of lipoic acid as a vaccine adjuvant.
背景技术Background technique
佐剂是一种能够增强对疫苗组分抗原特异性免疫应答或改变免疫反应的物质。在疫苗制剂中，佐剂的功能主要包括：增强疫苗抗原的免疫原性；促进细胞免疫和体液免疫，优化免疫应答，促进免疫能力较弱人群中的免疫应答；增进抗原与黏膜之间的传递以及免疫接触；减少疫苗成分中抗原的需求量以及在实施过程中的免疫接种次数；优化抗原结构，维持抗原构象等。佐剂的种类丰富，根据其功能，可分为运载传递系统和免疫刺激性佐剂。前者包括运载体即能与半抗原结合的一类具有免疫原性质的物质，还包括对整个疫苗系统起运输传递和衬托作用的一类物质。根据佐剂的来源，可分为细菌性、非细菌性、微生物性、细胞因子类以及合成体类等。根据理化性质，可分为颗粒性、凝胶性、乳胶佐剂等。跟据其性能，可分为治疗性佐剂、免疫刺激性佐剂、黏膜佐剂以及基因佐剂等。An adjuvant is a substance that enhances or modifies the immune response specific to an antigen in a vaccine component. In vaccine preparations, the functions of adjuvants mainly include: enhancing the immunogenicity of vaccine antigens; promoting cellular immunity and humoral immunity, optimizing immune responses, and promoting immune responses in immunocompromised populations; enhancing the transmission between antigens and mucous membranes And immune exposure; reduce the demand for antigens in vaccine components and the number of immunizations in the implementation process; optimize antigen structure, maintain antigen conformation, etc. There are many kinds of adjuvants, which can be divided into delivery system and immunostimulatory adjuvants according to their functions. The former includes the carrier, that is, a class of substances with immunogenic properties that can be combined with haptens, and also includes a class of substances that can transport, deliver and set off the entire vaccine system. According to the source of adjuvants, they can be divided into bacterial, non-bacterial, microbial, cytokines and synthetics. According to the physical and chemical properties, it can be divided into granular, gel, latex adjuvant and so on. According to its performance, it can be divided into therapeutic adjuvant, immunostimulatory adjuvant, mucosal adjuvant and gene adjuvant.
硫辛酸是一种存在于线粒体的辅酶，类似维他命，能消除加速老化与致病的自由基。硫辛酸在体内经肠道吸收后进入细胞，兼具脂溶性与水溶性的特性，因此可以在全身通行无阻，到达任何一个细胞部位，提供人体全面效能，是具脂溶性与水溶性的万能抗氧化剂。目前硫辛酸主要用于急性及慢性肝炎、肝硬变、肝性昏迷等。B族维生素，用于治疗急性及慢性肝炎、肝硬化、肝性昏迷、脂肪肝、糖尿病等。Lipoic acid is a coenzyme that exists in mitochondria, similar to vitamins, and can eliminate free radicals that accelerate aging and cause disease. Lipoic acid enters the cells after being absorbed by the intestinal tract in the body. It has both fat-soluble and water-soluble properties, so it can pass through the whole body unimpeded, reach any cell site, and provide comprehensive efficacy for the human body. It is a fat-soluble and water-soluble universal antibiotic. oxidizing agent. At present, lipoic acid is mainly used for acute and chronic hepatitis, liver cirrhosis, hepatic coma, etc. B vitamins are used to treat acute and chronic hepatitis, liver cirrhosis, hepatic coma, fatty liver, diabetes, etc.
发明内容Contents of the invention
本发明的目的一方面是拓展硫辛酸的新的应用领域，另一方面是提供一种更高效的疫苗佐剂，增强对兔巴氏杆菌病疫苗抗原特异性免疫应答。The purpose of the present invention is to expand the new application field of lipoic acid on the one hand, and to provide a more efficient vaccine adjuvant to enhance the specific immune response to the vaccine antigen of pasteurellosis in rabbits.
为了实现上述目的，本发明采用了以下技术方案：In order to achieve the above object, the present invention adopts the following technical solutions:
硫辛酸作为兔巴氏杆菌病疫苗佐剂的应用Application of lipoic acid as an adjuvant for pasteurellosis vaccine in rabbits
与现有技术相比较，本发明具备的有益效果：Compared with the prior art, the present invention has the beneficial effects:
将硫辛酸作为兔巴氏杆菌病疫苗佐剂能够显著提高免疫效率降低死亡率，并且安全、有效、不会引起毒副作用。Using the lipoic acid as the adjuvant of the pasteurellosis vaccine in rabbits can significantly improve the immune efficiency and reduce the mortality rate, and is safe and effective without causing toxic and side effects.
具体实施方式detailed description
下面通过实施例对本发明的技术方案作进一步阐述。The technical solution of the present invention will be further elaborated below through examples.
实施例1Example 1
(1)简介(1 Introduction
兔巴氏杆菌病是由Fo型多杀性巴氏杆菌引起的，其血清型为7：A、5：A，家兔中较常发生，一般无季节性，以冷热交替、气温骤变，闷热、潮湿多雨季节发生较多。改病的传统防治方法主要是平时加强饲养管理，改善环境卫生，改善兔子食欲为主，注意保暖防寒，防治寄生虫病等；定期进行检疫；兔舍、用具要严格消毒。预防时，可用兔巴氏杆菌氢氧化铝菌苗肌肉注射或禽巴氏杆菌菌苗免疫肌肉注射，每年两次，对预防本病有一定效果。病兔可用链霉素、诺氟沙星、增效磺胺及头孢菌素等治疗。Pasteurellosis in rabbits is caused by Pasteurella multocida of Fo type. Its serotypes are 7:A and 5:A. It occurs more frequently in rabbits and generally has no seasonality. , Happens more in sultry, humid and rainy seasons. The traditional prevention and treatment methods for disease improvement are mainly to strengthen feeding and management, improve environmental sanitation, improve rabbit appetite, pay attention to keeping warm and cold, prevent and control parasitic diseases, etc.; conduct regular quarantine; rabbit houses and utensils must be strictly sterilized. For prevention, intramuscular injection of rabbit Pasteurella aluminum hydroxide vaccine or poultry Pasteurella vaccine immunization intramuscular injection, twice a year, has a certain effect on the prevention of this disease. Sick rabbits can be treated with streptomycin, norfloxacin, synergistic sulfonamides and cephalosporins.
(2)免疫试验(2) Immunization test
将30只生长健康状态良好的平均体重1.2千克的中国白兔随机分配成三组：对照组、疫苗组和疫苗+硫辛酸组；对照组每只白兔肌肉注射1毫升生理盐水；疫苗组每只白兔肌肉注射1毫升市售兔用巴氏杆菌灭活菌苗；疫苗+硫辛酸组每只白兔肌肉注射1毫升市售兔用巴氏杆菌灭活菌苗和内含硫辛酸200μmoL的混合物。第一次注射后第8天再次进行一次注射，第一次注射后第20天，采用多杀巴氏杆菌攻毒，剂量为450cfu/只，观察15天，统计白兔的死亡情况，并计算相对免疫保护率，结果如表1所示。30 healthy Chinese white rabbits with an average weight of 1.2 kg were randomly assigned to three groups: the control group, the vaccine group and the vaccine+lipoic acid group; each white rabbit in the control group was intramuscularly injected with 1 ml of normal saline; White rabbits were intramuscularly injected with 1 ml of commercially available Pasteurella vaccine for rabbits; each white rabbit in the vaccine + lipoic acid group was intramuscularly injected with 1 ml of commercially available Pasteurella vaccine for rabbits and 200 μmoL of lipoic acid mixture. On the 8th day after the first injection, another injection was carried out. On the 20th day after the first injection, Pasteurella multocida was used to challenge the poison, and the dose was 450cfu/only. Observed for 15 days, counted the death of the white rabbits, and calculated The relative immune protection rate, the results are shown in Table 1.
表1试验结果Table 1 Test results
表1中相对免疫保护率一是与对照组相比的计算结果，二是与疫苗组相比的计算结果，从表1可以看出，试验白兔接受市售兔用巴氏杆菌灭活菌苗免疫后，与对照组相比，白兔死亡率有所下降。而疫苗+硫辛酸共同免疫后，比疫苗组的相对免疫保护率提高了66.67％，说明硫辛酸能够提高市售兔用巴氏杆菌灭活菌苗的保护效率。The relative immune protection rate one in table 1 is the calculation result compared with the control group, and the second is the calculation result compared with the vaccine group. As can be seen from table 1, the test white rabbit accepts commercially available pasteurella inactivated bacteria for rabbits. After immunization with the vaccine, the mortality rate of white rabbits decreased compared with the control group. However, after co-immunization with vaccine + lipoic acid, the relative immune protection rate of the vaccine group increased by 66.67%, indicating that lipoic acid can improve the protective efficiency of commercially available Pasteurella inactivated vaccines for rabbits.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610913659.5A CN106563124A (en) | 2016-10-19 | 2016-10-19 | Application of lipoic acid as vaccine adjuvant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610913659.5A CN106563124A (en) | 2016-10-19 | 2016-10-19 | Application of lipoic acid as vaccine adjuvant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106563124A true CN106563124A (en) | 2017-04-19 |
Family
ID=58534036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610913659.5A Pending CN106563124A (en) | 2016-10-19 | 2016-10-19 | Application of lipoic acid as vaccine adjuvant |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106563124A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101431997A (en) * | 2006-03-03 | 2009-05-13 | 马威苏德公司 | Melatonin and immunostimulating substance-based compositions |
| CN101909646A (en) * | 2008-01-08 | 2010-12-08 | 阿尔克-阿贝洛有限公司 | Allergy vaccine composition for mucosal administration |
| CN102438611A (en) * | 2009-05-19 | 2012-05-02 | 默克雪兰诺股份公司 | Use of a combination of d-aspartic and l-aspartic acids or salts thereof for the treatment of male infertility |
| WO2015007337A1 (en) * | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| CN104717974A (en) * | 2012-06-06 | 2015-06-17 | 比奥诺尔免疫有限公司 | Vaccine |
| WO2015086738A2 (en) * | 2013-12-11 | 2015-06-18 | Bionor Immuno As | Hiv vaccine |
-
2016
- 2016-10-19 CN CN201610913659.5A patent/CN106563124A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101431997A (en) * | 2006-03-03 | 2009-05-13 | 马威苏德公司 | Melatonin and immunostimulating substance-based compositions |
| CN101909646A (en) * | 2008-01-08 | 2010-12-08 | 阿尔克-阿贝洛有限公司 | Allergy vaccine composition for mucosal administration |
| CN102438611A (en) * | 2009-05-19 | 2012-05-02 | 默克雪兰诺股份公司 | Use of a combination of d-aspartic and l-aspartic acids or salts thereof for the treatment of male infertility |
| CN104717974A (en) * | 2012-06-06 | 2015-06-17 | 比奥诺尔免疫有限公司 | Vaccine |
| WO2015007337A1 (en) * | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| WO2015086738A2 (en) * | 2013-12-11 | 2015-06-18 | Bionor Immuno As | Hiv vaccine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sha et al. | Polysaccharides from Pinus massoniana pollen improve intestinal mucosal immunity in chickens | |
| Chen et al. | The immune-adjuvant activity and the mechanism of resveratrol on pseudorabies virus vaccine in a mouse model | |
| Wang et al. | Immunoadjuvant effects of bacterial genomic DNA and CpG oligodeoxynucleotides on avian influenza virus subtype H5N1 inactivated oil emulsion vaccine in chicken | |
| CN103157108B (en) | Immune modulator composition and pharmaceutical composition thereof and application | |
| CN104258389A (en) | Vaccine composition as well as preparation method and application thereof | |
| WO2015050179A1 (en) | Mucosal vaccine composition | |
| EP3076997B1 (en) | Swine vaccine against prrs and lawsonia intracellularis | |
| US20070224219A1 (en) | dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants | |
| CN102000332B (en) | Composite adjuvant for duck bird flu oral mucosal immunization | |
| WO2015050178A1 (en) | Nasal mucosal vaccine composition | |
| EP2925354A1 (en) | Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida | |
| CN106563124A (en) | Application of lipoic acid as vaccine adjuvant | |
| JP2013526504A (en) | Vaccine against Mycoplasma hyonyum monnier suitable for administration in the presence of maternally derived antibodies | |
| CN106421777A (en) | Application of resveratrol as vaccine adjuvant | |
| CN106267183B (en) | Live vaccine composition containing adjuvant and preparation method and application thereof | |
| Amini et al. | Evaluation of the immunogenicity of diphtheria toxoid conjugated to salmonella typhimurium-derived OPS in a mouse model: a potential vaccine candidate against salmonellosis | |
| Hung et al. | Gingyo‐San Enhances Immunity and Potentiates Infectious Bursal Disease Vaccination | |
| CN102973730B (en) | Chinese medicament for animals with functions of clearing heat and removing toxicity, resisting virus and improving body immunity and preparation method thereof | |
| Ezeibe et al. | In vitro and in vivo effects of aluminium magnesium silicate on infectious bursal disease virus in chicken. | |
| CN116457004A (en) | Combination vaccine for protecting pigs from various diseases | |
| MX2023009192A (en) | Vaccine for mycoplasma bovis. | |
| RU2396978C1 (en) | Method for prevention of cattle leukosis development | |
| RU2408370C2 (en) | Method of influenza vaccination of birds | |
| JP2020079308A (en) | Antibody inducer against virus infections for land animals other than human, and adjuvant thereof | |
| CN100402090C (en) | A compound adjuvant for mucosal immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170419 |
|
| WD01 | Invention patent application deemed withdrawn after publication |